Skip to content
akaturk Academic measurement
  1. Ana Dal Sağlık Bilimleri Temel Alanı
  2. Yan Dal Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji
Academic summary YÖKSİS and OpenAlex counted separately.
Articles 199
YÖKSİS199 OpenAlex0
Projects 11
Books 10
Proceedings 35

Citation impact

OpenAlex YÖKSİS articles matched in OpenAlex: 187
h-index 63 Percentile in Türkiye: 100 #3 of 2,315 at their university by h-index
i10-index
135
Total citations
24,475
Top 0.1% in Türkiye
Per article
130.9
FWCI
7.12
1.00 = world average
World top 1%
31
World top 10%
84

h-index and citations are computed from the citation counts of this academic’s YÖKSİS articles matched in OpenAlex (not Google Scholar, WoS or Scopus). Unmatched articles are not included.

Field ranking

YÖKSİS ?

Index quartiles

?
Scopus (SJR) 197
  • Q1 161 %81.7
  • Q2 17 %8.6
  • Q3 13 %6.6
  • Q4 6 %3.0
WoS (JCR) 197
  • Q1 133 %67.2
  • Q2 35 %17.7
  • Q3 9 %4.5
  • Q4 21 %10.6
TR Index 14 articles
OpenAlex citation percentile
Top 1%31
Top 10%84
Avg · n 186 %80.5
Other counts

Scopus (SJR)

  • Excluding abstracts 194 Q1 159 Q2 17 Q3 12 Q4 6
  • YÖKSİS rows 200

WoS (JCR)

  • Excluding abstracts 194 Q1 131 Q2 35 Q3 9 Q4 20
  • Best Q 197 Q1 133 Q2 35 Q3 8 Q4 21
  • YÖKSİS rows 200

Articles

Articles with YÖKSİS and OpenAlex source split; narrow by quartile or TR Index.

199articles

Journals with publications

70 journals

Narrow down

Scopus (SJR)
WoS (JCR)
TR Index

Article filter applied. Journal filter: The Lancet Clear filter ×

Article list

3 / 199 articles

  1. 2023 Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial LANCET DOI 10.1016/S0140-6736(22)02324-8 YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.3%
  2. 2021 CoronaVac efficacy data from Turkey \u2013 Authors' reply The Lancet DOI 10.1016/S0140-6736(21)02286-8 YÖKSİS SJR Q1 JCR Q1
  3. 2021 Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey The Lancet DOI 10.1016/S0140-6736(21)01429-X YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.9%

← Back to academicians